Shandong Lukang Pharmaceutical Co Ltd (SHG:600789) — Market Cap & Net Worth
Market Cap & Net Worth: Shandong Lukang Pharmaceutical Co Ltd (600789)
Shandong Lukang Pharmaceutical Co Ltd (SHG:600789) has a market capitalization of $1.24 Billion (CN¥8.48 Billion) as of May 23, 2026. Listed on the SHG stock exchange, this China-based company holds position #8203 globally and #2056 in its home market, demonstrating a -3.34% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shandong Lukang Pharmaceutical Co Ltd's stock price CN¥8.11 by its total outstanding shares 1045189778 (1.05 Billion). Analyse cash flow conversion of Shandong Lukang Pharmaceutical Co Ltd to see how efficiently the company converts income to cash.
Shandong Lukang Pharmaceutical Co Ltd Market Cap History: 2015 to 2026
Shandong Lukang Pharmaceutical Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $1.51 Billion to $1.24 Billion (-0.55% CAGR).
Shandong Lukang Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shandong Lukang Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.24x
Shandong Lukang Pharmaceutical Co Ltd's market cap is 0.24 times its annual revenue
Latest Price to Earnings (P/E) Ratio
12.31x
Shandong Lukang Pharmaceutical Co Ltd's market cap is 12.31 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.10 Billion | $2.51 Billion | $29.10 Million | 0.44x | 37.73x |
| 2017 | $901.22 Million | $2.60 Billion | $114.24 Million | 0.35x | 7.89x |
| 2018 | $858.28 Million | $3.33 Billion | $161.39 Million | 0.26x | 5.32x |
| 2019 | $1.07 Billion | $3.73 Billion | $121.25 Million | 0.29x | 8.84x |
| 2020 | $1.40 Billion | $4.21 Billion | $227.88 Million | 0.33x | 6.14x |
| 2021 | $1.13 Billion | $4.92 Billion | $89.10 Million | 0.23x | 12.65x |
| 2022 | $1.10 Billion | $5.62 Billion | $138.01 Million | 0.20x | 7.98x |
| 2023 | $1.09 Billion | $6.15 Billion | $246.17 Million | 0.18x | 4.44x |
| 2024 | $1.46 Billion | $6.23 Billion | $394.62 Million | 0.23x | 3.70x |
| 2025 | $1.38 Billion | $5.77 Billion | $112.30 Million | 0.24x | 12.31x |
Competitor Companies of 600789 by Market Capitalization
Companies near Shandong Lukang Pharmaceutical Co Ltd in the global market cap rankings as of May 23, 2026.
Key companies related to Shandong Lukang Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #500 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #550 globally with a market cap of $48.03 Billion USD ( CN¥328.20 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #554 globally with a market cap of $47.66 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #612 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #500 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #550 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $48.03 Billion | CN¥51.45 |
| #554 | GALDERMA GROUP AG | NYSE:GALDY | $47.66 Billion | $40.64 |
| #612 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €14.00 |
Shandong Lukang Pharmaceutical Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Shandong Lukang Pharmaceutical Co Ltd's market cap moved from $1.51 Billion to $ 1.24 Billion, with a yearly change of -0.55%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.24 Billion | -10.29% |
| 2025 | CN¥1.38 Billion | -5.34% |
| 2024 | CN¥1.46 Billion | +33.75% |
| 2023 | CN¥1.09 Billion | -0.84% |
| 2022 | CN¥1.10 Billion | -2.31% |
| 2021 | CN¥1.13 Billion | -19.45% |
| 2020 | CN¥1.40 Billion | +30.55% |
| 2019 | CN¥1.07 Billion | +24.92% |
| 2018 | CN¥858.28 Million | -4.77% |
| 2017 | CN¥901.22 Million | -17.92% |
| 2016 | CN¥1.10 Billion | -27.27% |
| 2015 | CN¥1.51 Billion | -- |
End of Day Market Cap According to Different Sources
On May 22nd, 2026 the market cap of Shandong Lukang Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.24 Billion USD |
| MoneyControl | $1.24 Billion USD |
| MarketWatch | $1.24 Billion USD |
| marketcap.company | $1.24 Billion USD |
| Reuters | $1.24 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Shandong Lukang Pharmaceutical Co Ltd
Shandong Lukang Pharmaceutical Co.,Ltd. operates as a pharmaceutical company in China. The company provides analgesics and antipyretics; gastrointestinal; endocrine; cardio-cerebrovascular; anti-infective; and other human formulation products. It offers human and veterinary active pharmaceutical ingredient; veterinary formulation; bio-pesticides; and amino acid. The company also exports its produ… Read more